Table 3.
Clinicopathological features of PTCs from 1994 to 2015
| Period | 94–95 | 96–97 | 98–99 | 00–01 | 02–03 | 04–05 | 06–07 | 08–09 | 10–11 | 12–13 | 14–15 | Total | P for difference | P for trend |
| Age, year | 46.9±14.3 | 43.1±10.7 | 41.1±12.9 | 44.9±14.8 | 44.6±14.5 | 43.8±12.4 | 44.6±12.4 | 42.7±12.4 | 43.9±11.2 | 43.9±11.1 | 43.6±10.9 | 43.7±11.3 | 0.643 | |
| Male, n
(%) |
5 (33.3) | 3 (17.6) | 6 (35.3) | 11 (28.2) | 18 (36) | 34 (31.8) | 60 (32.4) | 115 (30.0) | 227 (29.6) | 366 (26.6) | 616 (30.4) | 1461 (29.3) | 0.434 | 0.664 |
| Female, n
(%) |
10 (66.7) | 14 (82.4)*† | 11 (64.7.0)* | 28 (71.8)* | 32 (64)*† | 73 (68.2)† | 125 (67.6)*† | 268 (70.0)*† | 541 (70.4)*† | 1010 (73.4)* | 1407 (69.6)* | 3519 (70.7) | ||
| Size‡, cm | 2.3±1.1 | 2.6±1.9 | 2.1±1.3 | 2.2±1.6 | 2.2±1.4 | 2.2±1.6 | 1.7±1.1*† | 1.5±1.0b | 1.3±0.9*† | 1.2±0.8*† | 1.2±0.9† | 1.4±1.0 | <0.001 | |
| crPTC, n
(%) |
13 (86.7) | 15 (88.2) | 12 (70.6) | 32 (82.1) | 41 (82.0) | 87 (81.3) | 118 (63.8)* | 238 (62.1)† | 375 (48.8)*† | 696 (50.6)b | 1486 (73.5)* | 3113 (62.5) | <0.001 | 0.213 |
| mPTC, n
(%) |
2 (13.3) | 2 (11.8) | 5 (29.4) | 7 (17.9) | 9 (18.0) | 20 (18.7) | 67 (36.2) | 145 (37.9) | 393 (51.2) | 680 (49.4) | 537 (26.5) | 1866 (37.5) | ||
| LNM, n
(%) |
5 (33.3) | 5 (29.4) | 7 (41.2) | 22 (56.4) | 17 (34) | 27 (25.2) | 55 (29.7) | 96 (25.1) | 192 (25.0) | 372 (27.0) | 414 (20.5)* | 1212 (24.3) | <0.001 | <0.001 |
| No-LNM, n
(%) |
10 (66.7) | 12 (70.6) | 10 (58.8) | 17 (43.6) | 33 (66) | 80 (74.8) | 130 (70.3) | 287 (74.9) | 576 (75.0) | 1004 (73.0) | 1609 (79.5) | 3768 (75.7) | ||
| Total | 15 | 17 | 17 | 39 | 50 | 107 | 185 | 383 | 768 | 1376 | 2023 | <0.001 | <0.001 |
*Percentages significantly different from the previous year.
†Percentages significantly different within the period of 08–09.
‡Mean diameter.
crPTC, clinical relevant papillary thyroid carcinoma; LN, lymph node; LNM, lymph node metastasis; mPTC, micropapillary thyroid carcinoma.